Figure 3
From: Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics
Assessment of methylation changes in OS PDXs. (a) For each PDX, the absolute difference (βPatient - βXenograft) is calculated at each probe and binned into 1% methylation difference increments (described by the colour scale); the percentage of probes showing each methylation difference level is shown in the individual plots. (b) Number and percentage of probes in each comparison changing by 0.51 or more, corresponding to all probes going from fully unmethylated to fully methylated and vice versa.